4D Molecular Therapeutics (FDMT) Other Working Capital Changes (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Other Working Capital Changes data on file, last reported at -$878000.0 in Q1 2026.

• On a quarterly basis, Other Working Capital Changes fell 6171.43% year-over-year to -$878000.0 in Q1 2026; TTM through Mar 2026 was -$1.1 million, a 38.4% increase from a year earlier, with the FY2025 full-year figure at -$209000.0, up 87.34% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$878000.0, down from $2.1 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for FDMT reached as high as $4.0 million in Q1 2026 and fell as low as -$2.7 million in Q3 2025.
• Historically, Other Working Capital Changes has averaged $369411.8 across 5 years, with a median of $565000.0 in 2023.
• On a YoY basis, Other Working Capital Changes climbed as much as 224.07% in 2025 and fell as far as 77033.33% in 2025.
• Year by year, Other Working Capital Changes stood at -$1.2 million in 2022, then soared by 42.39% to -$719000.0 in 2023, then plunged by 139.22% to -$1.7 million in 2024, then jumped by 224.07% to $2.1 million in 2025, then plunged by 141.14% to -$878000.0 in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were -$878000.0 in Q1 2026, $2.1 million in Q4 2025, and -$2.3 million in Q3 2025.